Renal Denervation Momentum Could Be A Game Changer For Medtronic’s (MDT) Chronic Disease Strategy

• In recent months, analysts have highlighted Medtronic’s progress in its Symplicity Spyral renal denervation system, which already has FDA approval and is on track for Medicare coverage beginning in October 2025, supporting expectations for stronger demand in hypertension treatment.
• This focus on renal denervation complements Medtronic’s broader push into high-need areas such as cardiac ablation and diabetes care, reinforcing its position in complex chronic disease management.
• Next, we’ll examine how the momentum in renal denervation and related growth areas shapes Medtronic’s broader investment narrative for investors.

Find 43 companies with promising cash flow potential yet trading below their fair value.

What Is Medtronic's Investment Narrative?

To own Medtronic, you need to be comfortable with a steady, large-cap medical device company that leans on diversified franchises, incremental product innovation, and a long dividend track record rather than rapid expansion. Recent updates around the Symplicity Spyral renal denervation system, alongside progress in cardiac ablation, diabetes devices, and robotics, reinforce the near term growth story but do not fundamentally change the main catalysts: execution on new technology rollouts, regulatory milestones, and converting its pipeline into consistent revenue and margin gains. The ongoing recalls in neuromodulation and cannula products, plus mixed external ratings, keep product quality, pricing pressure, and execution risk firmly in view. With the share price still lagging analyst targets, the near term question is whether Medtronic can translate its broad pipeline and acquisitions into cleaner, faster earnings momentum.

Medtronic's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Seven Simply Wall St Community fair value views span roughly US$83.91 to US$98, underscoring how differently private investors read Medtronic’s prospects. As you compare those views with the current recall activity and the company’s push into renal denervation and robotics, it becomes clearer why opinions can diverge so widely and why checking several perspectives can sharpen your own expectations.

Explore 7 other fair value estimates on Medtronic - why the stock might be worth just $83.91!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Medtronic research is our analysis highlighting 6 key rewards that could impact your investment decision.
• Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com